Advanced glycation end products in neurodegeneration: More than early markers of oxidative stress?

Annals of Neurology

Volumn 44, Issue 3 SUPPL. 1, 1998, Pages

  Munch G ^b   Gerlach, M ^a   Sian, J ^a   Wong, A ^b   Riederer, P ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; SUPEROXIDE;

CONFERENCE PAPER; CROSS LINKING; DEGENERATIVE DISEASE; HUMAN; NERVE CELL NECROSIS; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0031719122     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440713     Document Type: Conference Paper

References (30)

1. Simonian NA, Coyle JT. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 1997;36:83-106
2. Meister A. Glutathione deficiency produced by inhibition of its synthesis and its reversal: applications in research and therapy. Pharmacol Ther 1991;51:155-194
3. Halliwell B. Free radicals, antioxidants and human disease: curiosity, cause or consequence? Lancet 1994;344:721-724
4. Gerlach M, Riederer P, Youdim MBH. Molecular mechanisms for neurodegeneration: Synergism between reactive oxygen species, calcium and excitotoxic amino acids. Adv Neurol 1996;69: 177-194
5. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996;47:5161-170
6. Owen AD, Schapira AHV, Jenner P, Marsden CD. Indices of oxidative stress in Parkinsons disease, Alzheimers disease and dementia with Lewy bodies. J Neural Transm 1997;51:S167-173
7. Castellani R, Smith MA, Richey PL, Perry G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 1996;737:195-200
8. Smith MA, Taneda S, Richey PL, et al. Advanced Maillard reaction end products are associated with Alzheimer's disease pathology. Proc Natl Acad Sci USA 1994;91:5710-5714
9. Smith MA, Sayre LM, Monnier VM, Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci 1995;18:172-176
10. Vitek MP, Bhattacharya K, Glendening JM, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 1994;91:4766-4770
11. Wells-Knecht MC, Thorpe SR, Baynes JW. Pathways of formation of glycoxidation products during glycation of collagen. Biochemistry 1995;34:15134-15141
12. Sian J, Gerlach M, Riederer P. The role of altered glutathione status in the development of Parkinson's disease. In: Shaw CA, ed. Glutathione in the central nervous system. Bristol: Taylor & Francis, 1998:287-304
13. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 1990;173:932-939
14. Schmidt AM, Hori O, Cao R, et al. RAGE, a novel cellular receptor for advanced glycation endproducts. Diabetes 1996;45: 77-80
15. Hunot S, Brugg B, Ricard D, et al. Nuclear translocation of NFκB is increased in dopaminergic neurons of patients with Parkinsons disease. Proc Natl Acad Sci USA 1997;94:7531-7536
16. Yan SD, Chen X, Schmidt AM, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994;91:7787-7791
17. Yan SD, Yan SF, Chen X, et al. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nature Med 1995;1:693-699
18. Mogi M, Harada M, Kondo T, et al. Interleukin-1β, interleukin-6, epiderminal growth factor and transforming growth factor-α are elevated in the brain of Parkinsonian patients. Neurosci Lett 1994;180:147-150
19. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin 1β and interleukin 6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1996;202:17-20
20. Münch G, Thome J, Foley P, Schinzel R, Riederer P. Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res Rev 1997;23:134-143
21. Münch G, Thome J, Double K, Schinzel R, Palm D, Riederer P. Advanced glycation endproducts and oxidative stress - a vicious circle in neurodegeneration? Alzheimers Dis Rev 1996;1: 71-74
22. Sian J, Dexter DT, Jenner P, Marsden CD. Decrease in nigral glutathione in Parkinson's disease. Br J Pharmacol 1991;104: 281P
23. Sofic E, Lange KW, Jellinger K, et al. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992;142:128-130
24. Sian J, Dexter DT, Jenner P, Mardsen CD. Glutathione related enzymes in brain in basal ganglia degenerative disorders. Br J Pharmacol 1992;107:428P
25. Ambani LM, Van Woert MH, Murphy S. Brain peroxidase and catalase activity in Parkinson's disease brain. Arch Neurol 1975; 32:114-116
26. Saggu H, Cooksey J, Dexter D, et al. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 1989;53:692-697
27. Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515-520
28. Sofic E, Riederer P, Heinsen H, et al. Increased iron (III) and total iron content in post-mortem substantia nigra of Parkinson brain. J Neural Transm 1988;74:199-205
29. Dexter DT, Carter CJ, Wells FR, Lees A, Jenner P, Marsden CD. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-389
30. Sanchez-Ramos JR, Övervik E, Ames BN, et al. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′deoxyguanosine) is increased in nigrostriatum of Parkinson's disease brain. Neurodegeneration 1994;3:197-204